LIPT1 and in situ carcinoma: As shown in Figures 4A–E, CIS treatment significantly increased the protein expression levels of pro-cuproptotic protein, FDX1, LIAS, and LIPT1, but pretreatment with CUR (5 μg/mL) and CUR/GOQDs (5 or 15 μg/mL) significantly inhibited the expression levels of these proteins.